Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study

[1]  A. Korshunov,et al.  Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome. , 2009, Archives of pathology & laboratory medicine.

[2]  R. Yamanaka.  [Molecular-targeted therapy for malignant glioma]. , 2009, Brain and nerve = Shinkei kenkyu no shinpo.

[3]  R. Gilbertson,et al.  Making a tumour's bed: glioblastoma stem cells and the vascular niche , 2007, Nature Reviews Cancer.

[4]  J. Rich,et al.  Cancer stem cells in radiation resistance. , 2007, Cancer research.

[5]  D. Reardon,et al.  Molecularly targeted therapy for malignant glioma , 2007, Cancer.

[6]  Pierre-Marie Martin,et al.  Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Stupp,et al.  Methylguanine methyltransferase testing in glioblastoma: when and how? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Tonn,et al.  Expression of VEGFR3 in glioma endothelium correlates with tumor grade , 2007, Journal of Neuro-Oncology.

[9]  T. Dawson,et al.  Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma , 2007, Brain Research.

[10]  S. Paek,et al.  Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: A clinicopathological study using fluorescence in situ hybridization , 2007, Neuropathology : official journal of the Japanese Society of Neuropathology.

[11]  L. de Ridder,et al.  Progression of astrocytomas and meningiomas: an evaluation in vitro , 2007, Cell proliferation.

[12]  Y. Katayama,et al.  Aberrant Hypermethylation of p14ARF and O6‐methylguanine‐DNA Methyltransferase Genes in Astrocytoma Progression , 2007, Brain pathology.

[13]  B. Bataille,et al.  Prognostic value of increase in transcript levels of Tp73 ΔEx2-3 isoforms in low-grade glioma patients , 2006, British Journal of Cancer.

[14]  C. Sommer,et al.  Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Alí,et al.  Telomerase activity and hTERT mRNA expression in glial tumors. , 2006, International journal of oncology.

[16]  W. Hall,et al.  Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. , 2006, Neurosurgical focus.

[17]  E. Holland,et al.  Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.

[18]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[19]  D. Bigner,et al.  Glioblastoma multiforme and the epidermal growth factor receptor. , 2005, The New England journal of medicine.

[20]  David J. Yang,et al.  The natural history of EGFR and EGFRvIII in glioblastoma patients , 2005, Journal of Translational Medicine.

[21]  Isaac Yang,et al.  Gliomas: advances in molecular analysis and characterization. , 2005, Surgical neurology.

[22]  A. Pellín,et al.  Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme. , 2005, Clinical neuropathology.

[23]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.

[25]  M. West,et al.  Gene expression profiling and genetic markers in glioblastoma survival. , 2005, Cancer research.

[26]  M. Varella‐Garcia,et al.  Glioblastomas in the older old. , 2005, Archives of pathology & laboratory medicine.

[27]  F. Angileri,et al.  Expression of Telomeric Repeat Binding Factor-1 in Astroglial Brain Tumors , 2005, Neurosurgery.

[28]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[29]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[30]  Y. Katayama,et al.  O-Methylguanine-DNA Methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course , 2004 .

[31]  H. Mehdorn,et al.  Glioblastoma multiforme-report of 267 cases treated at a single institution. , 2005, Surgical neurology.

[32]  Gordon C Jayson,et al.  Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[33]  M. Paz,et al.  CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  T. Tamiya,et al.  Loss of heterozygosity on chromosome 10q associated with malignancy and prognosis in astrocytic tumors, and discovery of novel loss regions. , 2004, Oncology reports.

[35]  S. Toms,et al.  Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. , 2004, International journal of radiation oncology, biology, physics.

[36]  L. Puricelli,et al.  EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas , 2004, Journal of surgical oncology.

[37]  C. Miracco,et al.  In situ detection of telomeres by fluorescence in situ hybridization and telomerase activity in glioblastoma multiforme: correlation with p53 status, EGFR, c-myc, MIB1, and Topoisomerase IIalpha protein expression. , 2003, International journal of oncology.

[38]  Y. Katayama,et al.  Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[40]  Anthony Asher,et al.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.

[41]  Y. Roussos,et al.  O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  O. Chinot,et al.  Clinical implications of quantitative real-time RT–PCR analysis of hTERT gene expression in human gliomas , 2003, British Journal of Cancer.

[43]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[44]  D. Louis,et al.  DMBT1 polymorphisms: relationship to malignant glioma tumorigenesis. , 2002, Cancer research.

[45]  Y. Nakazato,et al.  The expression of cell cycle regulatory proteins in oligodendroglial tumors. , 2002, Clinical neuropathology.

[46]  Jacqueline Palmari,et al.  PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. , 2002, International journal of radiation oncology, biology, physics.

[47]  P. Black,et al.  Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[49]  Y. Yonekawa,et al.  Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas , 2000, Journal of neuropathology and experimental neurology.

[50]  M. Kurrer,et al.  Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. , 1999, The American journal of pathology.

[51]  P. O’Connell,et al.  A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. , 1999, Neuro-oncology.

[52]  K. Hoang-Xuan,et al.  Mutational analysis of the PTEN gene in gliomas: Molecular and pathological correlations , 1999 .

[53]  D. Louis,et al.  PTEN mutations in gliomas and glioneuronal tumors , 1998, Oncogene.

[54]  Jan Mollenhauer,et al.  DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours , 1997, Nature Genetics.

[55]  C. Rhee,et al.  Loss of heterozygosity on chromosome 10, 13q(Rb), 17p, and p53 gene mutations in human brain gliomas. , 1995, Journal of Korean medical science.

[56]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[57]  A. Verma.  Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsMellinghoff IK, Wang MY, Vivanco I, etal (Univ of California, Los Angeles; Univ of California, San Francisco; Univ of California, San Diego; et al) N Engl J Med 353:2012–2024, 2005§ , 2007 .

[58]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[59]  P. Loehrer.  Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma , 2006 .